Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable ...
Regulus jumps after data from early-stage trial for kidney disease therapy (update)
Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...
Regulus shares surge on Wells Fargo upgrade, clinical update
Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.4% following an upgrade from Wells Fargo analyst ...
Regulus stock surges on positive trial results
Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Soleno Therapeutics SLNO shares increased by 38.8% to $67.98 during Thursday's pre-market session. The company's market cap stands at $2.9 billion. Ocean Biomedical OCEA shares moved upwards by 23.05% ...